A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM282 in Healthy Adult Participants

Trial Profile

A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM282 in Healthy Adult Participants

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs NGM 282 (Primary)
  • Indications Diabetes mellitus
  • Focus Adverse reactions
  • Sponsors NGM Biopharmaceuticals
  • Most Recent Events

    • 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
    • 04 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov
    • 08 Jul 2013 Planned End Date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top